Towards a Platform Chromatography Purification Process for Adeno-Associated Virus (AAV)

被引:0
作者
Bogdanovic, Alexandra [1 ,2 ,3 ]
Donohue, Nicholas [1 ]
Glennon, Brian [1 ,2 ]
Mcdonnell, Susan [2 ]
Whelan, Jessica [2 ,3 ,4 ]
机构
[1] APC Ltd, Dublin, Ireland
[2] Univ Coll Dublin, Sch Chem & Bioproc Engn, Dublin, Ireland
[3] Synth & Solid State Pharmaceut Ctr SSPC, Limerick, Ireland
[4] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin, Ireland
关键词
adeno-associated virus; chromatography; platform process; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; VECTORS; IDENTIFICATION; STRATEGIES; RECOVERY; RECEPTOR; CAPTURE; BINDING; PROTEIN;
D O I
10.1002/biot.202400526
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Adeno-associated virus (AAV) is a versatile viral vector technology that can be engineered for specific functionality in vaccine and gene therapy applications. One of the major challenges in AAV production is the need for a GMP-ready platform-based approach to downstream processing, as this would lead to a standardized method for multiple products. Chromatography has huge potential in AAV purification, as it is a scalable method that would enable manufacturing to a high degree of purity, potency, and consistency. Multiple factors need to be considered when developing a chromatography platform, including the chromatography type, format, and mode of operation, along with other commercial considerations that have not been comprehensively reviewed until now. In addition to chromatography factors, this review will also consider the current understanding of AAV characteristics: this will include net surface charge, structural properties, and size, as well as their interactions with metal ions or receptors, and how this impacts the development of a chromatography platform.
引用
收藏
页数:15
相关论文
共 54 条
[1]  
AdamsonSmall L., 2020, Cell Gene Therapy Insights, V6, P1249, DOI [10.18609/cgti.2020.138, DOI 10.18609/CGTI.2020.138]
[2]   Downstream process development strategies for effective bioprocesses: Trends, progress, and combinatorial approaches [J].
Baumann, Pascal ;
Hubbuch, Juergen .
ENGINEERING IN LIFE SCIENCES, 2017, 17 (11) :1142-1158
[3]   Comparison of batch and continuous multi-column protein A capture processes by optimal design [J].
Baur, Daniel ;
Angarita, Monica ;
Muller-Spath, Thomas ;
Steinebach, Fabian ;
Morbidelli, Massimo .
BIOTECHNOLOGY JOURNAL, 2016, 11 (07) :920-931
[4]  
Boenning K, 2020, CYTOTHERAPY, V22, pS186
[5]   Heparin: role in protein purification and substitution with animal-component free material [J].
Bolten, Svenja Nicolin ;
Rinas, Ursula ;
Scheper, Thomas .
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2018, 102 (20) :8647-8660
[6]   Viral vector platforms within the gene therapy landscape [J].
Bulcha, Jote T. ;
Wang, Yi ;
Ma, Hong ;
Tai, Phillip W. L. ;
Gao, Guangping .
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
[7]   Primary recovery and chromatographic purification of adeno-associated virus type 2 produced by baculovirus/insect cell system [J].
Chahal, Parminder S. ;
Aucoin, Marc G. ;
Kamen, Amine .
JOURNAL OF VIROLOGICAL METHODS, 2007, 139 (01) :61-70
[8]   Tuning mobile phase properties to improve empty and full particle separation in adeno-associated virus productions by anion exchange chromatography [J].
Chen, Dennis P. ;
Wei, Julie Y. ;
Warren, James C. ;
Huang, Chao .
BIOTECHNOLOGY JOURNAL, 2024, 19 (01)
[9]  
Corona Giuseppe, 1993, P343
[10]   The state of technological advancement to address challenges in the manufacture of rAAV gene therapies [J].
Destro, Francesco ;
Wu, Weida ;
Srinivasan, Prasanna ;
Joseph, John ;
Bal, Vivekananda ;
Neufeld, Caleb ;
Wolfrum, Jacqueline M. ;
Manalis, Scott R. ;
Sinskey, Anthony J. ;
Springs, Stacy L. ;
Barone, Paul W. ;
Braatz, Richard D. .
BIOTECHNOLOGY ADVANCES, 2024, 76